2-methyl-2-propanyl 1-(aminomethyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate | 1207175-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-methyl-2-propanyl 1-(aminomethyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate
• 英文别名: Tert-butyl 1-(aminomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate；tert-butyl 1-(aminomethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 1207175-15-2
• 化学式: C₁₅H₂₂N₂O₂
• mdl: MFCD11045240
• 分子量: 262.352
• InChiKey: VHKNZTWMVNWAOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.533
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methyl-2-propanyl 1-(aminomethyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate 在 吡啶 、 三氟乙酸 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 4.5h， 生成 2-(cyclopentanecarbonyl)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one
  参考文献：
  名称：

  Synthesis of new praziquantel analogues: Potential candidates for the treatment of schistosomiasis

  摘要：

  An efficient synthesis of antischistosomal drug praziquantel and analogues was achieved and the synthetic route designed was to afford structurally diverse analogues for better structure-activity relationship understanding. Total of nineteen PZQ analogues with structural variations at amide, piperazine and aromatic moieties have been synthesized and fully characterized. Among all the new analogues tested for antischistosomal activity, one dimethoxy tetrahydroisoquinoline analogue and two tetrahydro-beta-carboline analogues exhibited moderate activity against adult Schistosoma mansoni. Tetrahydro-beta-carboline analogues showed moderate activity whereas the presence of p-trifluoromethylbenzoyl and p-toluenesulphonyl moieties resulted in complete suppression of antischistosomal activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.108
• 作为产物：
  描述：

  tert-butyl 1-cyano-3,4-dihydroisoquinoline-2(1H)-carboxylate 在 氢气 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以79%的产率得到2-methyl-2-propanyl 1-(aminomethyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate
  参考文献：
  名称：

  Synthesis of new praziquantel analogues: Potential candidates for the treatment of schistosomiasis

  摘要：

  An efficient synthesis of antischistosomal drug praziquantel and analogues was achieved and the synthetic route designed was to afford structurally diverse analogues for better structure-activity relationship understanding. Total of nineteen PZQ analogues with structural variations at amide, piperazine and aromatic moieties have been synthesized and fully characterized. Among all the new analogues tested for antischistosomal activity, one dimethoxy tetrahydroisoquinoline analogue and two tetrahydro-beta-carboline analogues exhibited moderate activity against adult Schistosoma mansoni. Tetrahydro-beta-carboline analogues showed moderate activity whereas the presence of p-trifluoromethylbenzoyl and p-toluenesulphonyl moieties resulted in complete suppression of antischistosomal activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.108

文献信息

• DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS
  申请人：Rutgers, The State University of New Jersey

  公开号：US20180148408A1

  公开（公告）日：2018-05-31

  A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

  通过高通量筛选和引物开发的方法，识别化合物作为Keap1-Nrf2相互作用的直接抑制剂。Keap1-Nrf2相互作用的直接抑制剂比现有的间接抑制剂更具特异性，不受各种不良影响，并且是化学预防和治疗各种涉及氧化应激和/或炎症的疾病或症状的潜在药物候选者，包括但不限于癌症、糖尿病、阿尔茨海默病和帕金森病。还公开了识别新化合物以及使用所识别的新化合物或含有这些化合物的组合物来预防或治疗与Keap1-Nrf2相互作用活性相关的疾病或症状的方法。
• Dpp-IV Inhibitors
  申请人：Edwards Paul John

  公开号：US20080176838A1

  公开（公告）日：2008-07-24

  The invention relates to compounds of formula (I) wherein R 1-9 , Z, n, X, A, and R b have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament for the treatment of type 2 diabetes mellitus, obesity and lipid disorders.

  该发明涉及式(I)的化合物，其中R1-9、Z、n、X、A和Rb的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及将其作为药物用于治疗2型糖尿病、肥胖和脂质紊乱的生产和使用。
• [EN] DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS<br/>[FR] INHIBITEURS DIRECTS DE L'INTERACTION KEAP1-NRF2 EN TANT QUE MODULATEURS DE L'INFLAMMATION PAR ANTI-OXYDANT
  申请人：UNIV RUTGERS

  公开号：WO2013067036A1

  公开（公告）日：2013-05-10

  A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

  一种通过高通量筛选和引物开发将化合物识别为直接抑制Keap1-Nrf2相互作用的方法。Keap1-Nrf2相互作用的直接抑制剂比现有的间接抑制剂更具特异性，且不受各种不良效应的影响，是潜在的化学预防和治疗剂的候选药物，可用于治疗涉及氧化应激和/或炎症的各种疾病或病症，包括但不限于癌症、糖尿病、阿尔茨海默病和帕金森病。还披露了识别新化合物和利用所识别的新化合物或含有这些化合物的组合物预防或治疗与Keap1-Nrf2相互作用活性相关的疾病或病症的方法。
• HETEROCYCLIC COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20190077786A1

  公开（公告）日：2019-03-14

  Disclosed are compounds of formula (I) below or pharmaceutically acceptable salts thereof: in which each of variables R 1 -R 6 , L, m, and n is defined herein. Also disclosed are a method for treating an opioid receptor-associated condition with a compound of formula (I) and a pharmaceutical composition containing same.

  揭示了下面的化合物的结构式（I）或其药用盐：其中变量R1-R6、L、m和n在此处有定义。还揭示了使用结构式（I）的化合物治疗阿片受体相关疾病的方法，以及含有该化合物的药物组合物。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2015200709A1

  公开（公告）日：2015-12-30

  The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本公开涉及治疗癌症和肿瘤疾病的组合物和方法。本文提供了替代吡啶衍生物化合物和包含该化合物的制药组合物。该化合物和组合物对于抑制组蛋白去甲基化酶具有用途。此外，该化合物和组合物对于治疗癌症，例如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等具有用途。